Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …

It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype
that we have previously shown to be highly efficient for discovery of genetic associations …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

SARS-CoV-2–infected individuals may suffer a multi–organ system disorder known as “long
COVID” or post-acute sequelae of SARS-CoV-2 infection (PASC). There are no standard …

Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …